0001127602-13-003959.txt : 20130204 0001127602-13-003959.hdr.sgml : 20130204 20130204170221 ACCESSION NUMBER: 0001127602-13-003959 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130131 FILED AS OF DATE: 20130204 DATE AS OF CHANGE: 20130204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDS ARTHUR T CENTRAL INDEX KEY: 0001134106 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 13570826 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2013-01-31 0001062822 LEXICON PHARMACEUTICALS, INC./DE LXRX 0001134106 SANDS ARTHUR T 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 1 1 President & CEO Common Stock 2013-01-31 4 M 0 73700 A 911088 D Common Stock 2013-01-31 4 F 0 21434 2.11 D 889654 D Common Stock 817500 I By Sands Associates L.P. Common Stock 60000 I By Spouse As Custodian For Children Restricted Stock Units (Phantom Stock) 2013-01-31 4 M 0 73700 D Common Stock 73700 0 D Each restricted stock unit represents a contingent right to receive one share of common stock. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent. /s/ Arthur T. Sands, M.D., Ph.D. 2013-02-01